Generic Manufacturers May Gain Edge In New Patent Challenge Procedure At PTO
Apotex’s challenge of Alcon’s Vigamox patent put PTO’s new inter partes review proceeding in the spotlight; 45 petitions have been filed in the biopharma sector.
You may also be interested in...
Rep. Bob Goodlatte’s Innovation Act would delay discovery, require more information to file suits, which could increase the time and expense of pursuing infringement cases.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
The agency's "Bad Ad" program issued a warning letter that claims the promotion for CooperSurgical's copper-containing intrauterine contraceptive lacked any safety information.